Biotech · Private company
Opthea Limited
Track this companyFree. Adds Opthea Limited to your Dealase workspace and tells you when its record changes.
Clinical trials40 recruiting or active
Pipeline programs10From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline10
- 0.5 mg ranibizumabPhase 3 · Neovascular Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- 2.0 afliberceptPhase 3 · Neovascular Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- 2.0 mg OPT-302Phase 3 · Neovascular Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- ShamPhase 3 · Neovascular Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- AfliberceptPhase 2 · Diabetic Macular EdemaClinicalTrials.gov · fetched Nov 12, 2026
- OPT-302Phase 2 · Diabetic Macular EdemaClinicalTrials.gov · fetched Nov 12, 2026
- OPT-302Phase 2 · Neovascular Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- ranibizumabPhase 2 · Neovascular Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- sham intravitreal injectionPhase 2 · Neovascular Age-related Macular DegenerationClinicalTrials.gov · fetched Nov 12, 2026
- Sham intravitreal injectionPhase 2 · Diabetic Macular EdemaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)PHASE3 · TERMINATED · started Mar 12, 2021ClinicalTrials.gov NCT04757636 · fetched Nov 12, 2026
- OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)PHASE3 · TERMINATED · started Mar 12, 2021ClinicalTrials.gov NCT04757610 · fetched Nov 12, 2026
- A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular EdemaPHASE1_PHASE2 · COMPLETED · started Jan 16, 2018ClinicalTrials.gov NCT03397264 · fetched Nov 12, 2026
- A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMDPHASE2 · COMPLETED · started Nov 6, 2017ClinicalTrials.gov NCT03345082 · fetched Nov 12, 2026